Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jewish General Hospital
Age
50–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Age≥ 50 years
Clinical stage T1c (normal digital rectal examination) or T2a (one palpable nodule on digital rectal examination)
PSA ≤10 ng / mL
Presence of cancer on biopsies (12 sampling biopsies plus 2-4 targeted biopsies on one side and limited to one or two contiguous areas of prostate: basic and middle or middle and apex).
Gleason score ≤ 7 (3+4)
Flowmetry \> 12 mL / sec for a voided volume of 125 mL
PVR \<100 mL
Patient with normal anal and rectal anatomy.
Patient with a condition corresponding to a classification of ASA 1 or 2.
Patient signing ICF and agreed for following monitoring
You may not be if
Patient with an ASA score 3.
Patient in clinical stage T1a, T1b, T2b, T2c or T3.
Patient with a tumor visible on MRI: Located at a distance less than 5 mm from the midline. Located less than 6 mm from the apex real
Metastatic lymph node or metastasis discovered by MRI and bone scan.
Patient previously treated for his prostate cancer by hormone therapy.
Patient with a distance between the rectal mucosa and prostate capsule over 8 mm thick
History of inflammatory bowel disease
Rectal fistula.
History of pelvic radiotherapy.
History of bladder cancer.
History of bladder neck sclerosis or urethral stenosis.
Patient with an implant located less than 1 cm from the treatment zone (stent, catheter).
Urogenital infection.
Latex allergy
Contraindication to MRI (pacemaker,metal prosthesis ...)
Patient participated in another clinical study within 30 days.
